A Rare Opportunity 

Tue, Nov 5th 2019

I attended the NORD 2019 Summit in Washington, DC a few weeks ago. It was my first chance to attend this conference organized by the National Organization for Rare Diseases and, admittedly, the first time I considered going.

Read More

On Novartis' Data Manipulation

Wed, Aug 21st 2019

The news this past week that scientists at Novartis manipulated data in comparability studies for their gene therapy (Zolgensma) was surprising and disheartening. You can read one of the 

Read More

Boeing 737 and Lessons Learned for Medical Device Industry

Tue, Jul 30th 2019
Recent tragic crashes of two Boeing 737 Max airplanes have sparked ongoing investigations into what went wrong and how this can be prevented in the future. Earlier this year on separate occasions, two Boeing 737 Max aircrafts were sent into irrecoverable nose dives, killing a combined total of 346 people by software that was originally designed to stabilize the aircraft under very rare, high-speed maneuver situations. This blog will review some initial findings as reported by the New York Times (1) and draw an analogy to very similar processes relied on by the Medical Device industry for patient safety.
Read More

Foundation NYC Recap

Mon, Jul 15th 2019

Halloran was proud to sponsor last week's Foundation NYC, an annual event for entrepreneurs and investors in the Biomedical space - specifically those based in New York City and its nearby areas.

Read More